Key facts
- This page summarizes William Walmsley Hall's Form 4 filing for Evofem Biosciences, Inc. (EVFM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 May 2021, 16:13.
William Walmsley Hall - 12 May 2021 Form 4 Insider Report for Evofem Biosciences, Inc. (EVFM)
- Reporting relationship
- Director
- Issuer ticker
- EVFM
- Reported as of
- 12 May 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Justin J. File, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
William Walmsley Hall filed Form 4 for Evofem Biosciences, Inc. (EVFM) on 13 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVFM
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +90,000
- Change %
- Price
- $0.000000
- Shares after
- 90,000
- Date
- 12 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,000
- Exercise price
- $1.25
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Hall's board and committee services.